Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
09 Jul 2020 7:00 am
RNS
Brilinta granted US FDA Priority Review for stroke
08 Jul 2020 7:00 am
RNS
Lynparza approved in the EU for pancreatic cancer
01 Jul 2020 3:00 pm
RNS
Total Voting Rights
30 Jun 2020 3:00 pm
RNS
Director/PDMR Shareholding
  7:00 am
RNS
Selumetinib granted Japan orphan drug designation
17 Jun 2020 3:03 pm
RNS
Holding(s) in Company
  3:00 pm
RNS
Holding(s) in Company
15 Jun 2020 7:00 am
RNS
Agreement to Supply Europe with COVID-19 Vaccine
11 Jun 2020 7:00 am
RNS
EMTN Programme Routine Technical Update
01 Jun 2020 3:00 pm
RNS
Total Voting Rights
  3:00 pm
RNS
Block listing Interim Review
  7:00 am
RNS
Lynparza EU CHMP opinion in pancreatic cancer
  7:00 am
RNS
Brilinta obtains additional US approval
29 May 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  1:00 pm
RNS
Enhertu DESTINY-Gastric01 results from ASCO 2020
  1:00 pm
RNS
Imfinzi sustained overall survival in CASPIAN
  7:00 am
RNS
Tagrisso unprecedented adjuvant lung cancer data
26 May 2020 10:30 am
RNS
Director/PDMR Shareholding
22 May 2020 7:00 am
RNS
Enhertu US orphan designation in gastric cancer
21 May 2020 7:00 am
RNS
AstraZeneca advances response to COVID-19 outbreak
20 May 2020 7:00 am
RNS
Lynparza approved in the US for prostate cancer
18 May 2020 7:00 am
RNS
Enhertu US Breakthrough status for lung cancer
  7:00 am
RNS
Bevespi Aerosphere approved in China for COPD
11 May 2020 7:00 am
RNS
Enhertu designated gastric cancer BTD
  7:00 am
RNS
Brazikumab rights recovered by AstraZeneca
  7:00 am
RNS
Lynparza gets broader US ovarian cancer approval
06 May 2020 7:00 am
RNS
Farxiga approved by FDA for heart failure (HFrEF)
01 May 2020 3:00 pm
RNS
Total Voting Rights
29 Apr 2020 4:00 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: first-quarter 2020 results
24 Apr 2020 7:00 am
RNS
Lynparza shows overall survival in prostate cancer
17 Apr 2020 11:00 am
RNS
Changes to arrangements for AGM
14 Apr 2020 7:00 am
RNS
Koselugo (selumetinib) approved in the US for NF1
  7:00 am
RNS
Tagrisso adjuvant trial overwhelmingly positive
02 Apr 2020 7:00 am
RNS
AstraZeneca divestment of Movantik completed
01 Apr 2020 3:00 pm
RNS
Total Voting Rights
31 Mar 2020 7:00 am
RNS
Director/PDMR Shareholding
30 Mar 2020 7:01 am
RNS
Imfinzi approved in US for small cell lung cancer
  7:00 am
RNS
Farxiga CKD trial early stop for positive efficacy
26 Mar 2020 7:00 am
RNS
Lokelma approved in Japan for hyperkalaemia
  7:00 am
RNS
Director/PDMR Shareholding
24 Mar 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  12:02 pm
RNS
Price Monitoring Extension
23 Mar 2020 4:40 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  12:08 pm
RNS
Second Price Monitoring Extn
  12:03 pm
RNS
Price Monitoring Extension
20 Mar 2020 10:20 am
RNS
Second Price Monitoring Extn
  10:15 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Director/PDMR Shareholding
19 Mar 2020 7:00 am
RNS
Lynparza granted orphan drug designation in Japan
17 Mar 2020 7:00 am
RNS
Imfinzi confirmed overall survival in CASPIAN
13 Mar 2020 4:35 pm
RNS
Price Monitoring Extension
12 Mar 2020 11:00 am
RNS
Notice of AGM
  7:00 am
RNS
Update on Phase III GY004 trial for cediranib
10 Mar 2020 7:00 am
RNS
Director/PDMR Shareholding
06 Mar 2020 7:00 am
RNS
Update on Phase III DANUBE trial in bladder cancer
04 Mar 2020 7:00 am
RNS
Filing of Form 20-F with SEC
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t